Consistent Safety Profile of Risankizumab Across Psoriasis and Psoriatic Arthritis

Consistent Safety Profile of Risankizumab Across Psoriasis and Psoriatic Arthritis

Saakshi Khattri, MD, discusses the comparable safety profile of risankizumab in psoriasis and psoriatic arthritis and the minimal need for routine laboratory monitoring.

In this discussion, Saakshi Khattri, MD, addresses whether the safety profile of risankizumab differs meaningfully between patients treated for psoriasis and those treated for PsA. Based on the integrated analysis across psoriatic disease indications, she reports that the overall safety signals appear consistent between these populations. There were no notable differences in adverse event patterns or rates that would warrant divergent monitoring strategies on the basis of the specific psoriatic disease phenotype.

Khattri also underscores the practical advantages of risankizumab’s safety profile from a day-to-day clinical operations standpoint. She notes that, aside from baseline tuberculosis testing—a step that she continues to perform both out of habit and in anticipation of prior authorization requirements—there is no routine laboratory monitoring mandated specifically for risankizumab in either psoriasis or PsA.

Furthermore, she highlights the absence of warnings or signals in the prescribing information related to candidiasis, major adverse cardiovascular events, malignancy, or inflammatory bowel disease in the current dataset.

For clinicians, Khattri suggests that this consistent, relatively streamlined safety and monitoring profile can simplify long-term management and follow-up for patients with psoriatic disease. Whether treating skin-only psoriasis or PsA, the lack of distinct safety concerns between these groups allows a uniform approach to counseling and monitoring, while still adhering to standard-of-care screening and vigilance for comorbidities inherent to chronic inflammatory disease.